HBM Healthcare Investments — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Biohaven is a pharmaceutical company that discovers, develops, and commercializes medications for neurological and neuropsychiatric diseases, including epilepsy, pain, mood disorders, OCD, spinocerebellar ataxia, and spinal muscular atrophy.
BiotechHealthtechMedical DevicesConnecticut, US
Vlad Coric(Chairman & Chief Executive Officer)inVlad Coric, M.D.(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsOberland CapitalOUP (Osage University Partners)RA Capital+3 more
BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).
BiotechHealthtechMedical DevicesSan Diego, US
Jay M. Short(Executive Officer, Director)Richard A. Waldron(Executive Officer)inCarolyn Short(Director)
Co-investorsKeshif VenturesPappas CapitalPfizer Venture InvestmentsPappas CapitalPfizer VenturesSoleus Capital
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Founder)
BoardIvan Trifunovich(Director)John Wesley(Founder)
Co-investors8VCAisling CapitalHBM PartnersJacket River Capital PartnersMission Bay CapitalMission Biocapital+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.








